Thyroid Function and Circulating Antithyroid Antibodies in Myasthenia Gravis

矫毓娟,许贤豪,张华,国红,谢琰臣,吕继辉,刘江红,乔立艳,殷剑,魏雪飞,王红,孟晓梅
DOI: https://doi.org/10.3969/j.issn.1006-2963.2004.02.001
2004-01-01
Abstract:Objective To explore the clinical characteristics of myasthenia gravis(MG) with alteration of thyroid function and/or with circulating antithyroid antibodies. Methods The clinical data of 267 patients with MG were reviewed retrospectively. Thyroid function was evaluated by FT 3, FT 4 and TSH. The presence of circulating antithyroglobulin antibodies (TGAb), antiperoxidase antibody (TPOAb) and antimicrosomal antibodies (TMAb) were measured in 264 patients. Results There were 79.4% euthyroidism. The abnormality included thyrotoxicosis (5.2%), preclinical hyperthyroidism (0.4%), preclinical essential hypothyroidism (2.6%), secondary hypothyroidism (0.7%) and uncertainty (11.6%). In our study, 44/264(16.7%) myasthenic patients were TGAb-positive, 15/92 (16.3%) were TPOAb-positive and 20/172 (11.6%) were TMAb- positive. Antibody-positive MG-patients were more popular in generalized type ( P 0.01) of the abnormal thyroid function group. Comparing with the antibody-positive MG-patients, antibody-negative inclined to have earlier onset age of MG. Furthermore, as to the MG-patients with abnormal thyroid function parameters, they were more susceptible to thymic hyperplasia and thymoma ( P 0.05), and the courses of this disease were much more prolonged ( P 0.05). Conclusions MG coexistence with thyrotoxicosis and other thyroid diseases are not infrequent. Early diagnosis and timely treatment are critical to a good prognosis.
What problem does this paper attempt to address?